Effect of Aqueous Extract of Azadirachta indica Leaves on Pharmacokineics and Pharmacodynamics of Glipizide

Author(s): Sugandha Chaudhari*, Shitalkumar Zambad, Mohammed Ali.

Journal Name: Drug Metabolism Letters

Volume 13 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: Polypharmacy, that is, two (or more) drugs administered together, may cause chemical or pharmacological interactions. Such interactions may alter the effect of either agent, leading to decrease or increase effectiveness of the drugs, which may cause adverse effects. The co-intake of complementary and alternative medicines with therapeutic medicine are supposed to influence pharmacodynamics or pharmacokinetics of the latter.

Objective: This study was conducted to determine the interaction of glipizide (GZ) with an aqueous extract of Azadirachta indica (AZI) leaves.

Method: The pharmacokinetics and pharmacodynamics of glipizide was evaluated in High Fat diet (HFD) and streptozotocin induced diabetic Sprague-Dawley rats. Two doses of the AZI leaf extract (250 and 500 mg/kg) were administered alone or in combination with GZ (5 mg/kg) and serum glucose during oral glucose tolerance test, AST, ALT, and ALP levels were as estimated. In vitro CYP3A activity of AZI at 50 µg and 100 µg was assessed using liver microsomes.

Results: In the glucose tolerance test, AZI and GZ showed a hypoglycemic effect. However, the hypoglycemic effect was lower when AZI was administered in combination with GZ compared with GZ alone. AZI at 100 µg has shown significant potentiation of CYP3A activity. AZI (500 mg/kg) pretreatment significantly decreased AUC and increased Tmax to 8 h.

Conclusion: This indicated that the pharmacokinetics and pharmacodynamics of GZ altered by AZI might be due to the induction of CYP3A activity. In conclusion, AZI can decrease the bioavailability of GZ, and hence, it should be cautiously used.

Keywords: Pharmacodynamics, pharmacokinetics, glipizide, Azadirachta indica, P-glycoprotein, Cmax, AUC.

[1]
Gupta, R.C.; Nammi, S.; Bensoussan, A.; Bilinski, K.; Roufogalis, B.D. Interaction between antidiabetic drugs and herbs: an overview of mechanism of action and clinical implication. Diabetol. Metab. Syndr., 2017, 9, 59.
[2]
Rai, A.; Eapen, C.; Prasanth, V.G. Interaction of herbs and glibenclamide: A review. ISRN Pharmacol., 2012, 2012, 1-3.
[3]
Patwardhan, B.; Vaidya, A.D.B.; Chorghade, M. Ayurveda and natural products drug discovery. Curr. Sci., 2004, 86(6), 789-799.
[4]
Said, O.; Fulder, S.; Khalil, K.; Azaizeh, H.; Kassis, E.; Saad, B. Maintaining a physiological blood glucose level with ‘Glucolevel’, a combination of four anti-diabetes plants used in the traditional Arab herbal medicine. Evid. Based Complement. Alternat. Med., 2008, 5(4), 421-428.
[5]
Khanna, N.; Goswami, M.; Sen, P.; Ray, A. Antinociceptive action of Azadirachta indica (neem) in mice: Possible mechanisms involved. Indian J. Exp. Biol., 1995, 33, 848-850.
[6]
Sen, P.; Mediratta, P.K.; Ray, A. Effects of Azadirachta indica A Juss on some biochemical, immunological and visceral parameters in normal and stressed rats. Indian J. Exp. Biol., 1992, 30, 1170-1175.
[7]
Kausik, B.; Chattopadhyay, I.K.; Banerjee, R.K.; Bandyopadhyay, U. Biological activities and medicinal properties of neem (Azadirachta indica). Curr. Sci., 2002, 82(10), 1336-1345.
[8]
Chattopadhyay, R.R.; Chattopadhyay, R.N.; Maitra, S.K. Effect of A. indica on hepatic glycogen in rats. Int. J. Pharmacol., 1993, 25, 174-175.
[9]
Mehrotra, R.; Bajaj, S.; Kumar, D. Use of complementary and alternative medicine by patients with diabetes mellitus. Natl. Med. J. India, 2004, 17(5), 243-245.
[10]
Chacko, E. Culture and therapy: Complementary strategies for the treatment of type-2 diabetes in an urban setting in Kerala, India. Soc. Sci. Med., 2003, 56, 1087-1098.
[11]
Goyal, M. Traditional plants used for the treatment of diabetes mellitus in Sursagar constituency, Jodhpur, Rajasthan-An ethnomedicinal survey. J. Ethnopharmacol., 2015, 174, 364-368.
[12]
Kradjan, W.A.; Takeuchi, K.Y.; Opheim, K.E.; Wood, F.C. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy, 1995, 15(4), 465-471.
[13]
Ravindra, B.P.; Vanishree, S.; Sujatha, S.; Kishore, K.K. Effect of carvedilol on the pharmacokinetics and pharmacodynamics of glipizide. Int. J. Pharm. Pharm. Sci., 2012, 4(3), 133-138.
[14]
Wensing, G. Glipizide: an oral hypoglycemic drug. Am. J. Med. Sci., 1989, 298, 69-71.
[15]
Brian, W.R. Hypoglycemic agents.In: Levy, R.H.; Thummel, K.E.; Tranger, W.F.; Haunsten, P.D.; Eichelbaum, M. Metabolic drug interactions.Philadelphia: , Lippincott Williams & Wilkins;. 2000.
[16]
Yu, C.P.; Wu, P.P.; Hou, Y.C.; Lin, S.P.; Tsai, S.Y.; Chen, C.T.; Chao, P.D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J. Agric. Food Chem., 2011, 59(9), 4644-4648.
[17]
Trease, G.E.; Evans, W.C. Trease and Evans Pharmacognosy 15thed ; Bailliere Tindall anacox: Landon,. , 2002.
[18]
Wrighton, S.A.; Schuetz, E.G.; Watkins, P.B.; Maurel, P.; Barwick, J.; Bailey, B.S. Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol. Pharmacol., 1985, 28, 312-321.
[19]
Umathe, S.N.; Dixit, P.V. kumar V.; Bansod K.U.; Wanjari M.M. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochem. Pharmacol., 2008, 75, 1670-1676.
[20]
Srinivasan, K.; Viswanad, B.; Asrat, L.; Kaul, C.L.; Ramarao, P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res., 2005, 52, 313-320.
[21]
Trinder, P. Modified assay procedure for the estimation of serum glucose using microwell reader. Ann. Clin. Biochem., 1969, 6, 24.
[22]
Astin, J.A. why patients use alternative medicine: Results of a national study. JAMA, 1998, 279(19), 1548-1553.
[23]
Druss, B.G.; Rosenheck, R.A. Association between use of unconventional therapies and conventional medical services. JAMA, 1999, 282(7), 651-656.
[24]
Eisenberg, D.M.; Davis, R.B.; Ettner, S.L. Trends in alternative medicine use in the United States. 1990-1997: results of a follow-up national survey. JAMA, 1998, 280(18), 1569-1575.
[25]
Kuo, G.M.; Hawley, S.T.; Weiss, L.T.; Balkrishnan, R.; Volk, R.J. Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. BMC Complement. Altern. Med., 2004, 4, 18.
[26]
Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed; Williams & Wilkins: Baltimore, USA, 1995.
[27]
Elliot, M.; Chithan, K.; Theoharis, C.T. The effects of plant flavanoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev., 2000, 52, 673-751.
[28]
Esmaeili, M.A.; Yazdanparas, R. Hypoglycemic effect of Teucrium polium: studies with rat pancreatic islets. J. Ethnopharmacol., 2004, 99, 27-30.
[29]
Sharma, S.B.; Nassir, A.; Prabhu, K.M.; Murthy, P.S. Antihyperglycemic effect of the fruit-pulp of Eugenia jambolana in experimental diabetes mellitus. J. Ethnopharmacol., 2006, 104, 367-373.
[30]
Yolanda, B.L.; Adriana, G.C. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. J. Nutr. Biochem., 2006, 17, 1-13.
[31]
Ortiz-A, R.R.; Garcia-J, S.; Castillo-E, P.; Ramirez-A, G.; Villalobos, M.R.; Estrada-S, S. α-Glucosidase inhibitory activity of the methanolic extract from Tournefortia hartwegiana: An antihyperglycemic agent. J. Ethnopharmacol., 2007, 109, 48-53.
[32]
Obatomi, D.K.; Bikomo, E.O.; Temple, V.J. Antidiabetic properties of the African mistletoe in streptozotocin-induced diabetic rats. J. Ethnopharmacol., 1994, 43, 13-17.
[33]
Rajeswari, S.; Kumar, A.; Gandhi, M.; Swaminathan, S. Association between lipid profile and liver function tests in diabetic patients. Int. J. Pure App. Biosci., 2014, 2(4), 26-31.
[34]
Philip, R.; Mathias, M.; Suchetha, K.N.; Damodara, G.K.M.; Shetty, K.J. Evaluation of relationship between markers of liver function and the onset of type 2 diabetes. NUJHS, 2014, 4(2), 90-93.
[35]
Agarawa, J. Prevalence of elevated hepatic enzymes among north Indian patients with type 2 diabetes mellitus. SUJHS, 2015, 1(1), 3-6. (b) Maxwell, D.B.; Fisher, E.A.; Ross-Clunis, H.A.; Estep, H.L. Serum alkaline phosphatase in diabetes mellitus. J. Am. Coll. Nutr., 1986, 5(1), 55-59.
[36]
Robert, J.K.; Barbara, B. Hodgson Saunders Nursing Drug Handbook 2017 - E-Book; Elsevier: United states of America, 2017.
[37]
Kale, B.P.; Kothekar, B.P.; Tayade, H.P.; Jaju, J.B.; Mateenuddin, M. Effect of aqueous extract of Azardirachta indica leaves on hepatotoxicity induced by antitubercular drugs in rats. Int. J. Pharmacol., 2003, 35, 177-180.
[38]
Chattopadhyay, R.R.; Sarkar, S.K.; Ganguly, S.; Banerjee, R.N.; Basu, T.K.; Mukherjee, A. Hepatoprotective activity of Azadirachta indica leaves on paracetamol induced hepatic damage in rats. Indian J. Exp. Biol., 1992, 30, 738-740.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 1
Year: 2019
Page: [19 - 24]
Pages: 6
DOI: 10.2174/1872312812666181106115247

Article Metrics

PDF: 27
HTML: 1
EPUB: 1
PRC: 1